KRAS and colorectal carcinoma: In KRYSTAL-1 (NCT03785249), the combination of cetuximab and adagrasib was given to 32 patients with previously treated metastatic KRAS G12C mutated CRC with no prior treatment with KRAS G12C inhibitors.